Claritev's PHCS Network Receives Twelfth Consecutive NCQA Accreditation in Credentialing
First certified in 2001, the PHCS Network underwent a rigorous review of its credentialing and recredentialing processes to maintain its NCQA Accreditation in Credentialing. The network was reaccredited for the maximum period of 3 years, which is valid through June 13, 2028.
Through the accreditation process, the NCQA auditor specifically remarked that Claritev:
Had dedicated and knowledgeable staff,
Prepared files facilitating a smooth file review, and
Made timely credentialing decisions.
'This twelfth consecutive NCQA Accreditation is a testament to the unwavering commitment and caliber of our team to uphold the highest standards in credentialing,' said Jerry Hogge, Chief Operating Officer of Claritev. 'It reflects our dedication to ensuring that healthcare professionals in the PHCS Network meet rigorous quality benchmarks, ultimately supporting better outcomes for the patients and partners we serve.'
The PHCS Network provides health plan members with seamless access to healthcare services across the country, with more than a million participating practitioners, 4,600 acute care facilities and 92,000 ancillaries.
About NCQA
NCQA accredits and certifies a wide range of health care organizations. It also recognizes clinicians and practices in key areas of performance. NCQA's Healthcare Effectiveness Data and Information Set (HEDIS®) is the most widely used performance measurement tool in health care, with over 60% of the US population enrolled in health plans that use the measure. NCQA can be found online at ncqa.org, on Twitter @ncqa, on Facebook at facebook.com/NCQA.org/ and on LinkedIn at linkedin.com/company/ncqa.
NCQA has reviewed and accredited Claritev's Credentialing functions for the PHCS Network only. For complete details on the scope of this review, visit www.ncqa.org.
About Claritev
Claritev, formerly known as MultiPlan, is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality. Led by a team of deeply experienced associates, data scientists, and innovators, Claritev provides cutting-edge solutions and services fueled by multiple data sources and over 40 years of claims repricing experience. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose–built solutions that support all key players – including payors, employers, patients, providers and third parties – Claritev aims to make healthcare more accessible and affordable for all. For more information, visit claritev.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
11 minutes ago
- Globe and Mail
Corebridge Financial Announces Pricing of Secondary Offering of Common Stock by AIG
Corebridge Financial, Inc. (NYSE: CRBG) today announced that the previously announced secondary offering by American International Group, Inc. (NYSE: AIG) of common stock of Corebridge Financial has priced at $33.65 per share. The offering is expected to close on August 8, 2025, subject to customary closing conditions. AIG, as the selling stockholder, has offered 30 million existing shares of common stock (out of approximately 538 million total shares of common stock outstanding) of Corebridge Financial, corresponding to approximately $1.0 billion of gross proceeds. AIG has also granted a 30-day option to the underwriter to purchase up to an additional 4.5 million shares. All of the net proceeds from the offering will go to AIG. Morgan Stanley & Co. LLC is acting as the underwriter for the offering. The offering of common stock is being made only by means of a prospectus and an accompanying prospectus supplement. Copies of the prospectus and accompanying prospectus supplement relating to the offering may be obtained from: Morgan Stanley & Co. LLC via mail at 180 Varick Street, 2nd Floor, New York, NY 10014. A registration statement relating to these securities was filed with the U.S. Securities and Exchange Commission ('SEC') on November 6, 2023, and became effective automatically. The registration statement may be obtained free of charge at the SEC's website at (EDGAR/Company Filings) under 'Corebridge Financial, Inc.' This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended. About Corebridge Financial Corebridge Financial, Inc. makes it possible for more people to take action in their financial lives. With more than $415 billion in assets under management and administration as of June 30, 2025, Corebridge Financial is one of the largest providers of retirement solutions and insurance products in the United States. We proudly partner with financial professionals and institutions to help individuals plan, save for and achieve secure financial futures.
Globe and Mail
20 minutes ago
- Globe and Mail
AvidXchange Announces Second-Quarter 2025 Financial Results
CHARLOTTE, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leading provider of accounts payable (AP) automation software and payment solutions for middle market businesses and their suppliers, today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Total revenue was $110.6 million, an increase of 5.2% year-over-year, compared with $105.1 million in the second quarter of 2024. Revenue included interest income of $10.6 million compared with $11.8 million in the second quarter of 2024. General and administrative expenses included transaction and deal costs of $6.4 million primarily related to the proposed plan of merger announced on May 6, 2025. GAAP net loss was $(9.5) million, compared with a GAAP net income of $0.4 million in the second quarter of 2024. Non-GAAP net income was $10.7 million, compared with $10.7 million in the second quarter of 2024. GAAP gross profit was $73.6 million, or 66.6% of total revenue, compared with $68.7 million, or 65.3% of revenue in the second quarter of 2024. Non-GAAP gross profit was $81.6 million, or 73.8% of total revenue, compared with $76.3 million, or 72.6% of revenue in the second quarter of 2024. Adjusted EBITDA was $17.4 million compared with $17.5 million in the second quarter of 2024. A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables following the financial statements in this press release. An explanation of these measures is also included below under the heading "Non-GAAP Measures and Other Performance Metrics." Second Quarter 2025 Key Business Metrics and Highlights: Total transactions processed in the second quarter of 2025 were 20.1 million, an increase of 1.8% from 19.7 million in the second quarter of 2024. Total payment volume in the second quarter of 2025 was $21.5 billion, an increase of 4.1% from $20.6 billion in the second quarter of 2024. Transaction yield in the second quarter of 2025 was $5.50, an increase of 3.2% from $5.33 in the second quarter of 2024. Financial Outlook & Earnings Teleconference As disclosed previously, due to its pending acquisition by TPG in partnership with Corpay, AvidXchange has suspended its previously issued financial outlook for fiscal 2025 and will not hold a teleconference to discuss its second quarter 2025 financial results. About AvidXchange™ AvidXchange is a leading provider of accounts payable ('AP') automation software and payment solutions for middle market businesses and their suppliers. AvidXchange's software-as-a-service-based, end-to-end software and payment platform digitizes and automates the AP workflows for more than 8,500 businesses and it has made payments to more than 1,350,000 supplier customers of its buyers over the past five years. To learn more about how AvidXchange is transforming the way companies pay their bills, visit Forward-Looking Statements Certain statements made in this press release constitute forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this press release that are not statements of historical fact and generally relate to future events, hopes, intentions, strategies, or performance may be deemed to be forward-looking statements, including, without limitation, statements regarding AvidXchange's pending acquisition by TPG in partnership with Corpay. These forward-looking statements are based on management's current expectations and beliefs as of the date they are made. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause AvidXchange's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including the risks discussed in AvidXchange's filings with the Securities and Exchange Commission ('SEC'), including AvidXchange's Annual Report on Form 10-K and other documents filed with the SEC, which may be obtained on the investor relations section of our website ( and on the SEC website at AvidXchange undertakes no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law. Non-GAAP Measures and Other Performance Metrics To supplement the financial measures presented in our press release in accordance with generally accepted accounting principles in the United States ('GAAP'), we also present the following non-GAAP measures of financial performance: Non-GAAP Gross Profit, Non-GAAP Gross Margin, Adjusted EBITDA, Non-GAAP Net Income (Loss) and Non-GAAP Earnings Per Share. A 'non-GAAP financial measure' refers to a numerical measure of our historical or future financial performance or financial position that is included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in our financial statements. We provide certain non-GAAP measures as additional information relating to our operating results as a complement to results provided in accordance with GAAP. The non-GAAP financial information presented herein should be considered in conjunction with, and not as a substitute for or superior to, the financial information presented in accordance with GAAP and should not be considered a measure of liquidity. There are significant limitations associated with the use of non-GAAP financial measures. Further, these measures may differ from the non-GAAP information, even where similarly titled, used by other companies and therefore should not be used to compare our performance to that of other companies. We have presented Non-GAAP Gross Profit, Adjusted EBITDA, Non-GAAP Net Income (Loss) and Non-GAAP Earnings Per Share in this press release. We define Non-GAAP Gross Profit & Gross Margin as revenue less cost of revenue excluding the portion of depreciation and amortization and stock-based compensation expense allocated to cost of revenues. We define Adjusted EBITDA as our net loss before depreciation and amortization, impairment and write-off of intangible assets, interest income and expense, income tax expense (benefit), stock-based compensation expense, transaction and acquisition-related costs expensed, change in fair value of derivative instrument, non-recurring items not indicative of ongoing operations, and charitable contributions of common stock. We define Non-GAAP Net Income (Loss) as net loss before amortization of acquired intangible assets, impairment and write-off of intangible assets, stock-based compensation expense, transaction and acquisition-related costs expensed, change in fair value of derivative instrument, non-recurring items not indicative of ongoing operations, acquisition-related effects on income tax, and charitable contributions of common stock. Non-GAAP income tax expense is calculated using our blended statutory rate except in periods of non-GAAP net loss when it is based on our GAAP income tax expense. In each case, non-GAAP income tax expense excludes the effects of acquisitions in the period on tax expense. We define Non-GAAP Earnings per Share as Non-GAAP Net Income (Loss) per diluted share. We believe the use of non-GAAP financial measures, as a supplement to GAAP measures, is useful to investors in that they eliminate items that are either not part of our core operations or do not require a cash outlay, such as stock-based compensation expense. Management uses these non-GAAP financial measures when evaluating operating performance and for internal planning and forecasting purposes. We believe that these non-GAAP financial measures help indicate underlying trends in the business, are important in comparing current results with prior period results and are useful to investors and financial analysts in assessing operating performance. Availability of Information on AvidXchange's Website Investors and others should note that AvidXchange routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts, and the Investor Relations section of AvidXchange's website. While not all information that AvidXchange posts to the Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, AvidXchange encourages investors, the media and others interested in AvidXchange to review the information that it shares at the Investor Relations link located at Users may automatically receive email alerts and other information about AvidXchange when enrolling an email address by visiting 'Email Alerts' in the 'Resources' section of AvidXchange's Investor Relations website Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Revenues $ 110,570 $ 105,132 $ 218,512 $ 210,730 Cost of revenues (exclusive of depreciation and amortization expense) 30,949 30,426 61,738 60,759 Operating expenses Sales and marketing 23,068 19,956 45,579 39,697 Research and development 26,975 25,008 52,357 50,912 General and administrative 33,510 22,635 62,458 46,895 Impairment and write-off of intangible assets - - - 162 Depreciation and amortization 8,479 9,208 17,148 18,515 Total operating expenses 92,032 76,807 177,542 156,181 Loss from operations (12,411) (2,101) (20,768) (6,210) Other income (expense) Interest income 4,480 5,979 8,621 12,541 Interest expense (2,010) (3,323) (4,016) (6,660) Other income 2,470 2,656 4,605 5,881 (Loss) income before income taxes (9,941) 555 (16,163) (329) Income tax (benefit) expense (477) 119 612 244 Net (loss) income $ (9,464) $ 436 $ (16,775) $ (573) Net (loss) income per share attributable to common stockholders, basic and diluted Basic $ (0.05) $ 0.00 $ (0.08) $ 0.00 Diluted $ (0.05) $ 0.00 $ (0.08) $ 0.00 Weighted average number of common shares used to compute net loss per share attributable to common stockholders, basic and diluted Basic 206,933,045 207,025,967 205,982,206 205,961,720 AvidXchange Holdings, Inc. Consolidated Balance Sheets (in thousands, except share and per share data) As of June 30, As of December 31, 2025 2024 Assets Current assets Cash and cash equivalents $ 335,773 $ 355,637 Restricted funds held for customers 1,148,195 1,250,346 Marketable securities 71,461 33,663 Accounts receivable, net of allowances of $4,362 and $4,279, respectively 50,988 51,671 Supplier advances receivable, net of allowances of $2,024 and $1,644 respectively 18,035 14,080 Prepaid expenses and other current assets 15,503 15,317 Total current assets 1,639,955 1,720,714 Property and equipment, net 96,632 97,592 Deferred customer origination costs, net 29,005 28,119 Goodwill 165,921 165,921 Intangible assets, net 65,235 71,068 Other noncurrent assets and deposits 7,087 6,297 Total assets $ 2,003,835 $ 2,089,711 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 20,482 $ 15,494 Accrued expenses 45,094 46,849 Payment service obligations 1,148,195 1,250,346 Deferred revenue 12,747 13,967 Current maturities of lease obligations under finance leases 36 103 Current maturities of lease obligations under operating leases 663 1,207 Current maturities of long-term debt 4,800 4,800 Total current liabilities 1,232,017 1,332,766 Long-term liabilities Deferred revenue, less current portion 10,640 11,856 Obligations under finance leases, less current maturities 63,342 63,025 Obligations under operating leases, less current maturities 1,655 1,969 Long-term debt 4,300 4,300 Other long-term liabilities 4,331 3,962 Total liabilities 1,316,285 1,417,878 Commitments and contingencies Stockholders' equity Preferred stock, $0.001 par value; 50,000,000 shares authorized, no shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Common stock, $0.001 par value; 1,600,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 207,695,309 and 204,335,860 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 208 204 Additional paid-in capital 1,718,132 1,685,644 Accumulated deficit (1,030,790) (1,014,015) Total stockholders' equity 687,550 671,833 Total liabilities and stockholders' equity $ 2,003,835 $ 2,089,711 AvidXchange Holdings, Inc. Three Months Ended June 30, Six Months Ended June 30, Reconciliation of Revenue to Non-GAAP Gross Profit and Non-GAAP Gross Margin 2025 2024 2025 2024 (in thousands) Total revenues $ 110,570 $ 105,132 $ 218,512 $ 210,730 Expenses: Cost of revenues (exclusive of depreciation and amortization expense) (30,949) (30,426) (61,738) (60,759) Depreciation and amortization expense (5,977) (6,034) (12,106) (12,098) GAAP Gross profit $ 73,644 $ 68,672 $ 144,668 $ 137,873 Adjustments: Stock-based compensation expense 1,996 1,625 3,980 2,857 Depreciation and amortization expense 5,977 6,034 12,106 12,098 Non-GAAP gross profit $ 81,617 $ 76,331 $ 160,754 $ 152,828 GAAP Gross margin 66.6 % 65.3 % 66.2 % 65.4 % Non-GAAP gross margin 73.8 % 72.6 % 73.6 % 72.5 % AvidXchange Holdings, Inc. Reconciliation of GAAP to Non-GAAP Measures (Continued) Three Months Ended June 30, Six Months Ended June 30, Reconciliation of Net Income (Loss) to Non-GAAP Net Income (Loss), including per share amounts 2025 2024 2025 2024 (in thousands, except share and per share data) Net income (loss) $ (9,464) $ 436 $ (16,775) $ (573) Exclude: Provision for income taxes (477) 119 612 244 Income (loss) before taxes (9,941) 555 (16,163) (329) Amortization of acquired intangible assets 2,859 3,414 5,744 6,827 Impairment and write-off of intangible assets - - - 162 Stock-based compensation expense 15,085 12,319 29,571 23,278 Transaction and acquisition-related costs (1) 6,449 - 8,445 - Non-recurring items not indicative of ongoing operations (2) (195) (1,976) 528 (630) Total net adjustments 24,198 13,757 44,288 29,637 Non-GAAP income (loss) before taxes 14,257 14,312 28,125 29,308 Non-GAAP income tax expense (2) 3,550 3,564 7,003 7,298 Non-GAAP net income (loss) $ 10,707 $ 10,748 $ 21,122 $ 22,010 Weighted-average shares used to compute Non-GAAP net income (loss) per share attributable to common stockholders, basic 206,933,045 207,025,967 205,982,206 205,961,720 Weighted-average shares used to compute Non-GAAP net income (loss) per share attributable to common stockholders, diluted 207,348,652 209,896,829 205,982,206 205,961,720 GAAP Net income (loss) per share attributable to common stockholders, basic and diluted $ (0.05) $ 0.00 $ (0.08) $ 0.00 Non-GAAP basic net income (loss) per share attributable to common stockholders, basic $ 0.05 $ 0.05 $ 0.10 $ 0.11 Non-GAAP basic net income (loss) per share attributable to common stockholders, diluted $ 0.05 $ 0.05 $ 0.10 $ 0.11 GAAP income (loss) per common share, basic and diluted $ (0.05) $ 0.00 $ (0.08) $ 0.00 Amortization of acquired intangible assets 0.01 0.02 0.03 0.03 Impairment and write-off of intangible assets - - - - Stock-based compensation expense 0.07 0.06 0.14 0.11 Transaction and acquisition-related costs 0.03 - 0.04 - Non-recurring items not indicative of ongoing operations (1) - (0.01) - - Provision for income taxes (0.02) (0.02) (0.03) (0.03) Adjustment to fully diluted earnings per share 0.01 - - - Non-GAAP diluted income (loss) per common share $ 0.05 $ 0.05 $ 0.10 $ 0.11 AvidXchange Holdings, Inc. Reconciliation of GAAP to Non-GAAP Measures (Continued) Three Months Ended June 30, Six Months Ended June 30, Reconciliation of Net Loss to Adjusted EBITDA 2025 2024 2025 2024 (in thousands) Net loss $ (9,464) $ 436 $ (16,775) $ (573) Depreciation and amortization 8,479 9,208 17,148 18,515 Impairment and write-off of intangible assets - - - 162 Interest income (4,480) (5,979) (8,621) (12,541) Interest expense 2,010 3,323 4,016 6,660 Provision for income taxes (477) 119 612 244 Stock-based compensation expense 15,085 12,319 29,571 23,278 Transaction and acquisition-related costs (1) 6,449 - 8,445 - Non-recurring items not indicative of ongoing operations (2) (195) (1,976) 528 (630) Adjusted EBITDA $ 17,407 $ 17,450 $ 34,924 $ 35,115 (1) For the three and six months ended June 30, 2025, this amount consists of transaction and deal costs incurred in connection with the proposed plan of merger announced on May 6, 2025 described in our unaudited consolidated financial statements. (2) For the three months ended June 30, 2025, this amount includes a $172 gain on lease buyout. For the three months ended June 30, 2024, this amount was primarily comprised of an insurance recovery of $2,110 for costs incurred in response to the cybersecurity incident that was detected in April 2023. For the six months ended June 30, 2025, this amount includes $618 in restructuring costs and a $172 gain on lease buyout. For the six months ended June 30, 2024 this amount includes $1,157 of severance costs and a net benefit of $1,808 of response costs incurred in connection with the cybersecurity incident.
Globe and Mail
41 minutes ago
- Globe and Mail
RFK Jr.'s cuts to vaccine funding threaten pandemic preparedness, Canadian health experts warn
Canadian experts in vaccines and infectious diseases say the decision by the U.S. government to terminate nearly US$500-million in funding for mRNA vaccine development is not just illogical but threatens pandemic preparedness. U.S. Health Secretary Robert F. Kennedy Jr. announced on Tuesday that 22 mRNA-based projects will be halted and no new projects will be green lit. He claimed data show these vaccines 'fail to protect effectively against upper respiratory infections like COVID and flu.' Vaccine specialists on both sides of the border have stressed that mRNA technology is safe and effective, in addition to being a necessary tool to prevent future pandemics. While mRNA research will continue elsewhere, Canadian experts said the U.S. cuts will be felt across the global scientific community. Kennedy's firing of U.S. immunization committee is worrisome, Canadian scientists say Pieter Cullis, a biochemist at the University of British Columbia whose discoveries with lipid membranes ultimately provided the delivery system for COVID-19 vaccines, said the decision is 'bewildering.' 'This is the most promising technology we have for diseases – rare diseases, infectious diseases, cancer, cardiovascular, you name it,' said Dr. Cullis. 'It's one of the most successful innovations in medicine in the last 10 years or longer and they're completely ignoring it.' Mr. Kennedy, a long-time vaccine skeptic, has made a number of changes to vaccine programming in the U.S. Earlier this year, he pulled back recommendations on COVID vaccinations for pregnant women and children. He also turfed the U.S. panel responsible for making vaccine recommendations. The Health Secretary said on Tuesday that funding will be shifted toward 'broader vaccine platforms that remain effective even as viruses mutate.' One of the earlier cuts at the U.S. Department of Health and Human Services, or HHS, was Moderna's contract to develop a human vaccine for bird flu – a disease of increasing concern. Allison McGeer, an infectious-diseases specialist at Mount Sinai Hospital in Toronto, said there is no other word to describe the recent U.S. cuts than 'nonsense.' She stressed that the production and distribution of COVID-19 vaccines, which have saved countless lives, was substantially a U.S. initiative and one that greatly benefitted Canada. But Canada can no longer rely on this partnership for pandemic preparedness. 'There's just no doubt that this puts an enormous hole in the work that's going on and, even if everybody else in the world tries to step in, it's going to be hard to make up this loss,' she said. Dr. McGeer said there is a lot of important work being undertaken in Canada on mRNA technology and it could be expanded. But while Canada feels the impact of tariffs imposed by Mr. Trump, she's worried investments in science will decrease. 'I'm undeniably very anxious that we will lose ground in Canada because we're looking for funding for prevention. Funding for prevention is always hard and even harder in our current economic situation,' said Dr. McGeer. Mr. Kennedy's latest comments on vaccines are also fuelling vaccine hesitancy and opposition, said Lynora Saxinger, an infectious-diseases specialist at the University of Alberta. She said the cuts signal the 'triumph of disinformation over science.' Dr. Saxinger said there is already a proportion of the Canadian population that aligns with the U.S. Her concern, however, is for people who are on the fence and could fall victim to disinformation by consuming it frequently. 'The fact that it's being elevated by the secretary of HHS does make it more likely that people who might not otherwise be paying a lot of attention will see more and more about this and it will undermine their trust in vaccines as well,' she said. 'We're reaching a point now where I think anything coming out of the U.S. that has to do with science and human health, you have to doubt it.' The Infectious Diseases Society of America, in a statement on Wednesday, said the recent cuts 'are deeply concerning and reflect an alarming pattern of the Administration's efforts to curtail vaccine research and sow unfounded doubt in vaccine safety and effectiveness.' With a file from the Associated Press
